🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Umeclidinium bromide

Found 56 matching trials

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

PHASE3

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powd...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-15

Trial ID

NCT01899742

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Tiotropium 18 mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

N/A

Study to collect the data on Chronic Obstructive Pulmonary Disease (COPD) p...

Status

Completed

Location

Ditmanson Medical Foundation Chia - Yi Christian Hospital

Start Date

2019-12-29

Trial ID

NCT04011475

Treatments Being Tested

Tiotropium + Olodaterol Other LABA/LAMA LAMA

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

N/A

This study looks at data from people with chronic obstructive pulmonary dis...

Status

Completed

Location

eMax health

Start Date

2021-12-17

Trial ID

NCT05169424

Treatments Being Tested

Trelegy Ellipta Stiolto Respimat Tiotropium + Olodaterol (5/5 mcg)Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

PHASE4

The primary objective of this study is to assess the effect of umeclidinium...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-14

Trial ID

NCT02799784

Treatments Being Tested

UMEC/VI TIO/OLO Albuterol/salbutamol

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

PHASE4

The primary objective of this study is to evaluate the effectiveness of TRE...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-10-14

Trial ID

NCT05535972

Treatments Being Tested

FF/UMEC/VI

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to further characterize the dose response of G...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-07-01

Trial ID

NCT01372410

Treatments Being Tested

GSK573719 GSK573719 GSK573719 GSK573719 GSK573719 GSK573719 Tiotropium Placebo

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

Previous Next